Virus therapy targets Hard-to-Treat endometrial cancer
NCT ID NCT03120624
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This early-stage trial tests a specially modified virus (VSV-hIFNbeta-NIS) given through an IV to people with advanced or recurrent endometrial cancer. The virus is designed to attack cancer cells while leaving healthy cells alone, and it includes a tracer to see where it goes in the body. Some participants also receive a second drug (ruxolitinib) to boost the virus's effect. The main goal is to find the safest dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug TJ037130 takes aim at advanced solid tumors
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Hormone blocker plus targeted drug shows promise against tough uterine cancer
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New drug duo shows promise for Tough-to-Treat endometrial cancer
- Heated chemo during surgery may fight ovarian cancer return